PUBLICATIONS

MEDIA

PRESS RELEASE

18 
September

2019 

Prilenia’s Pridopidine chosen to participate in the first ever ALS platform trial by the Sean M. Healey & AMG center for ALS at Mass General

18 
September

2019 

Prilenia’s Pridopidine chosen to participate in the first ever ALS platform trial by the Sean M. Healey & AMG center for ALS at Mass General

PUBLICATIONS

  • 2020 June 5
    Additional Safety and Exploratory Efficacy Data at 48 and 60 Months From Open-HART,
    an Open-Label Extension Study of Pridopidine in Huntington Disease

    Andrew McGarry , Peggy Auinger , Karl Kieburtz , Michal Geva , Munish Mehra , Victor Abler , Igor D Grachev , Mark Forrest Gordon , Juha-Matti Savola , Sanjay Gandhi , Spyridon Papapetropoulos , Michael Hayden
    Journal of Huntingtons Disease

    Link: https://pubmed.ncbi.nlm.nih.gov/32508327/

  • 2019 Sep
    Pridopidine Protects Neurons from Mutant-Huntingtin Toxicity via the Sigma-Receptor.
    Eddings CR, Arbez N, Akimov S, Geva M, Hayden MR, Ross CA.
    Neurobiology disease
    Link: https://www.ncbi.nlm.nih.gov/pubmed/31108174

  • 2019 May 16
    Impairment and Restoration of Homeostatic Plasticity in Cultured Cortical Neurons From a Mouse Model of Huntington Disease
    Smith-Dijak AI, Nassrallah WB, Zhang LYJ, Geva M, Hayden MR, Raymond LA.
    Frontiers in Cellular Neuroscience

    Link: https://www.ncbi.nlm.nih.gov/pubmed/31156395
     

  • 2019 Mar 1
    Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1G93A Model
    Ariel Ionescu, Tal Gradus, Topaz Altman, Roy Maimon, Noi Saraf Avraham, Michal Geva, Michael Hayden, Eran Perlson.
    Cell Death & Disease

    Link: https://www.ncbi.nlm.nih.gov/pubmed/30824685

  • 2019 Feb 12
    Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson’s Disease
    Veronica Francardo, Michal Geva, Francesco Bez, Quentin Denis, Lilach Steiner, Michael R. Hayden, M. Angela Cenci.
    Neurotherapeutics
    Link: https://www.ncbi.nlm.nih.gov/pubmed/30756361

  • 2018 Dec 27
    Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor.
    Ryskamp D, Wu L, Wu J, Kim D, Rammes G, Geva M, Hayden M, Bezprozvanny I.
    Neurobiology Disease

    Link: https://www.ncbi.nlm.nih.gov/pubmed/30594810

  • 2018 Dec 21
    Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
    Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR.
    Movement Disorder Society

    Link: https://www.ncbi.nlm.nih.gov/pubmed/30575996

  • 2018 May 21
    Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.
    Kusko R, Dreymann J, Ross J, Cha Y, Escalante-Chong R, Garcia-Miralles M, Tan LJ, Burczynski ME, Zeskind B, Laifenfeld D, Pouladi M, Geva M, Grossman I, Hayden MR.
    Molecular Neurodegeneration

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29783994 

  • 2017 Dec 7
    Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.
    Garcia-Miralles M, Geva M, Tan JY, Yusof NABM, Cha Y, Kusko R, Tan LJ, Xu X, Grossman I, Orbach A, Hayden MR, Pouladi MA.
    Journal of Clinical Investigation

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29212949 

  • 2017 Jan
    The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.
    Ryskamp D, Wu J, Geva M, Kusko R, Grossman I, Hayden M, Bezprozvanny I.
    Neurobiol Disease 
    Link: https://www.ncbi.nlm.nih.gov/pubmed/27818324
     

  • 2016 Sep 15
    Pridopidine activates neuroprotective pathways impaired in Huntington Disease.
    Geva M, Kusko R, Soares H, Fowler KD, Birnberg T, Barash S, -Wagner AM, Fine T, Lysaght A, Weiner B, Cha Y, Kolitz S, Towfic F, Orbach A, Laufer R, Zeskind B, Grossman I, Hayden MR.
    Human molecular genetics
    Link: https://www.ncbi.nlm.nih.gov/pubmed/27466197
     

 

PRESS RELEASE AND EVENTS

Prilenia Therapeutics raises $62.5M to fund late stage trials in HD and ALS

03
JUNE

2020

Presentation by Dr. Michael Hayden at the Jefferies
Virtual Conference 

03
JUNE

2020

18 
SEPTEMBER

2019 

Prilenia’s Pridopidine chosen to participate in the first ever ALS platform trial by the Sean M. Healey & AMG center for ALS at Mass General

 
CONTACT US

Email.  info@prilenia.com

Tel.  +972-77-5558482